In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
BACS data were available for 18 ME/CFS patients, 25 long COVID patients and 22 healthy controls
If the force was maintained for the required 3 seconds, a green tick indicated successful task performance during a single trial (see Supplementary Figure 3B)
Tirzepatide (Zepbound) combines GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, creating a dual mechanism that affects multiple pathways
N cng gy kh khn cho vic i li
Two severe adverse events were reported: viral meningitis (in cagrilintide 1.2 mg + semaglutide 2.4 mg) and an increase in serum creatinine (in placebo + semaglutide 2.4 mg), but both events were deemed unrelated to study treatment by the study investigator